AIM ImmunoTech Inc
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for … Read more
AIM ImmunoTech Inc - Asset Resilience Ratio
AIM ImmunoTech Inc (AIM) has an Asset Resilience Ratio of 21.59% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how AIM ImmunoTech Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down AIM ImmunoTech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.35 Million | 21.59% |
| Total Liquid Assets | $1.35 Million | 21.59% |
Asset Resilience Insights
- Good Liquidity Position: AIM ImmunoTech Inc maintains a healthy 21.59% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
AIM ImmunoTech Inc Industry Peers by Asset Resilience Ratio
Compare AIM ImmunoTech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for AIM ImmunoTech Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for AIM ImmunoTech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.44% | $2.28 Million | $8.61 Million | -12.93pp |
| 2023-12-31 | 39.37% | $7.63 Million | $19.38 Million | +21.75pp |
| 2022-12-31 | 17.63% | $7.14 Million | $40.49 Million | -10.41pp |
| 2021-12-31 | 28.03% | $16.18 Million | $57.70 Million | +27.26pp |
| 2020-12-31 | 0.78% | $501.00K | $64.58 Million | -35.37pp |
| 2019-12-31 | 36.14% | $7.31 Million | $20.22 Million | +25.12pp |
| 2018-12-31 | 11.02% | $1.53 Million | $13.85 Million | +6.13pp |
| 2017-12-31 | 4.89% | $695.00K | $14.21 Million | -13.44pp |
| 2016-12-31 | 18.33% | $3.46 Million | $18.87 Million | -11.46pp |
| 2015-12-31 | 29.80% | $6.79 Million | $22.80 Million | -17.59pp |
| 2014-12-31 | 47.39% | $13.95 Million | $29.44 Million | -7.18pp |
| 2013-12-31 | 54.57% | $17.39 Million | $31.87 Million | -17.77pp |
| 2012-12-31 | 72.34% | $41.74 Million | $57.70 Million | +9.71pp |
| 2011-12-31 | 62.64% | $27.25 Million | $43.51 Million | -0.62pp |
| 2010-12-31 | 63.25% | $32.69 Million | $51.68 Million | +46.21pp |
| 2007-12-31 | 17.04% | $3.94 Million | $23.14 Million | -41.42pp |
| 2006-12-31 | 58.46% | $18.38 Million | $31.43 Million | +8.30pp |
| 2005-12-31 | 50.17% | $12.38 Million | $24.67 Million | +18.69pp |
| 2004-12-31 | 31.48% | $7.92 Million | $25.17 Million | +20.33pp |
| 2003-12-31 | 11.15% | $1.50 Million | $13.40 Million | +1.96pp |
| 2002-12-31 | 9.19% | $555.00K | $6.04 Million | -34.93pp |
| 2001-12-31 | 44.12% | $5.31 Million | $12.04 Million | +8.48pp |
| 2000-12-31 | 35.64% | $4.66 Million | $13.07 Million | +20.15pp |
| 1999-12-31 | 15.49% | $2.20 Million | $14.20 Million | -- |